Skip to main content

View full-text article in PMC

. 2020 May 11;103(1):308–314. doi: 10.4269/ajtmh.19-0931

Table 2.

Intention-to-treat and per-protocol cure rates of both treatment groups

Treatment arms	Intention-to-treat analysis		Per-protocol analyses
Treatment arms	Initial cure rate	Definitive cure rate	Initial cure rate	Definitive cure rate
Miltefosine	75/78, (96.6%; 95% CI: 88.4–99%)	63/78 (80.8%; 95% CI: 69.95–88.5%)	75/75 (100%; 95% CI: 93.93–100%)	63/75 (84%; 95% CI: 73.32–91.1%)
Combination therapy	63/66 (95.5%; 95% CI: 86.43–98.8%)	63/66 (95.5%; 95% CI: 86.43–98.8%)	63/63 (100%; 95% CI: 92.84–100%)	63/63 (100%; 95% CI: 92.84–100%)